Loading...
Docoh

Medpace (MEDP)

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 37 countries.

MEDP stock data

Calendar

26 Jul 22
14 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 42.55M 42.55M 42.55M 42.55M 42.55M 42.55M
Cash burn (monthly) 13.43M 24.7M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 20.1M 36.97M n/a n/a n/a n/a
Cash remaining 22.45M 5.58M n/a n/a n/a n/a
Runway (months of cash) 1.7 0.2 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
18 Jul 22 Medpace Investors Common Stock Buy Acquire P No Yes 145 8,330 1.21M 5,513,639
18 Jul 22 Troendle August J. Common Stock Buy Acquire P Yes Yes 145 8,330 1.21M 5,513,639
14 Jul 22 Medpace Investors Common Stock Buy Acquire P No Yes 144.59 22,290 3.22M 5,505,309
14 Jul 22 Troendle August J. Common Stock Buy Acquire P Yes Yes 144.59 22,290 3.22M 5,505,309
20 May 22 Keating Ashley M. STOCK OPTION Common Stock Grant Acquire A No No 133.87 1,903 254.75K 1,903
13F holders Current Prev Q Change
Total holders 342 377 -9.3%
Opened positions 32 71 -54.9%
Closed positions 67 24 +179.2%
Increased positions 120 117 +2.6%
Reduced positions 152 149 +2.0%
13F shares Current Prev Q Change
Total value 6.07B 7.85B -22.7%
Total shares 42.75M 44.28M -3.5%
Total puts 46.4K 15.3K +203.3%
Total calls 114K 54.6K +108.8%
Total put/call ratio 0.4 0.3 +45.2%
Largest owners Shares Value Change
Cinven Capital Management 10.4M $451.26M 0.0%
Troendle August J. 5.64M $1.25B 0.0%
BLK Blackrock 3.79M $620.45M +0.9%
Vanguard 3.13M $511.75M -1.3%
Wasatch Advisors 2.73M $446.34M +12.1%
STT State Street 899.86K $147.21M +2.5%
IVZ Invesco 894.02K $146.25M -9.3%
Echo Street Capital Management 695.34K $113.75M +18.4%
Boston Trust Walden 674.99K $110.42M +38.2%
Dimensional Fund Advisors 656.86K $107.46M +1.5%
Largest transactions Shares Bought/sold Change
Wellington Management 0 -1.06M EXIT
Vulcan Value Partners 561.64K +329.02K +141.4%
Wasatch Advisors 2.73M +294.1K +12.1%
Norges Bank 0 -263.48K EXIT
Driehaus Capital Management 120.53K -227.93K -65.4%
BEN Franklin Resources 5.85K -210.75K -97.3%
Boston Trust Walden 674.99K +186.52K +38.2%
Arrowstreet Capital, Limited Partnership 32.38K -166.48K -83.7%
Millennium Management 171.52K +121.79K +244.9%
Polen Capital Management 4.56K -113.67K -96.1%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: added, anniversary, director, earlier, forward, preceding
Removed: add, discontinued, interbank, offered